Vhh chain of an anti-fp nanobody and uses thereof

By developing the VHH chain of anti-FP nanobodies, the problems of stability and low expression levels of anti-FP antibodies have been solved, enabling efficient and low-cost preparation of nanobodies and high-sensitivity ELISA and WB detection, which are suitable for nanomedical imaging and molecular biology detection.

CN122404546APending Publication Date: 2026-07-17DALIAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
DALIAN UNIV
Filing Date
2026-04-07
Publication Date
2026-07-17

AI Technical Summary

Technical Problem

Existing anti-FP antibodies suffer from poor stability, low expression yield, large batch-to-batch variability, high production costs, and non-specific interference in ELISA and WB experiments.

Method used

A VHH chain of an anti-FP nanobody was developed, containing a specific framework region (FR) and complementarity-determining region (CDR), with the amino acid sequence shown in SEQ ID NO.8. It can efficiently express and specifically recognize FP and is suitable for E. coli expression systems.

Benefits of technology

This study achieved high affinity, stability, and efficient expression of anti-FP nanobodies, reduced production costs, improved the accuracy and sensitivity of ELISA and WB experiments, and reduced non-specific interference.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122404546A_ABST
    Figure CN122404546A_ABST
Patent Text Reader

Abstract

本发明公开一种抗FP的纳米抗体的VHH链及其应用，属于纳米抗体技术领域。本发明的抗FP的纳米抗体的VHH链,包括框架区FR和互补决定区CDR,框架区FR包括FR1、FR2、FR3和FR4，互补决定区CDR包括:CDR1、CDR2和CDR3。其CDR区可特异性识别PfFtn独特抗原表位，避免交叉反应。该纳米抗体分子量约15kDa，可在大肠杆菌高效表达、批间差异小、成本低、免疫原性低，适配体内实验及临床相关应用。配套抗PfFtn抗体可直接应用于ELISA检测、WB实验等常规蛋白分析场景，助力靶蛋白定性与定量检测，为PfFtn重组融合蛋白分析鉴定、分子互作研究提供有效工具。
Need to check novelty before this filing date? Find Prior Art